---
title: "Nine-month all-oral regimen for MDR/RR-TB in Lesotho: safety and effectiveness by HIV status"
id: "medrxiv-7-nine-month-all-oral-regimen-for-mdr-rr-tb-in-lesotho-safety-and-effectiveness"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-7-nine-month-all-oral-regimen-for-mdr-rr-tb-in-lesotho-safety-and-effectiveness"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.04.26362253v1?rss=1"
published_at: "2026-09-09T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Nine-month all-oral regimen for MDR/RR-TB in Lesotho: safety and effectiveness by HIV status
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-7-nine-month-all-oral-regimen-for-mdr-rr-tb-in-lesotho-safety-and-effectiveness
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.04.26362253v1?rss=1)
- **Published At:** 2026-09-09T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Prospective observational cohort study of a nine-month, **all-oral** regimen for multidrug- and rifampicin-resistant tuberculosis (**MDR/RR-TB**) in Lesotho, carried out between 2020 and 2023. - The shortened regimen combined **bedaquiline**, **linezolid**, a fluoroquinolone, **delamanid**, and clofazimine. - 255 patients initiated the regimen; 161 (63.1%) were living with **HIV**. - Safety was assessed by frequency and timing of clinically relevant adverse events; the most common were **peripheral neuropathy** and **myelosuppression**, occurring regardless of HIV status. - Effectiveness outcomes included treatment status at end of treatment and **sustained treatment success** at 18 months after treatment initiation. - Unadjusted estimated sustained treatment success at 18 months was 86.4% overall (95% CI: 81.4%, 90.5%). - Sustained success by HIV status: 85.0% (95% CI: 78.2%, 90.4%) among people living with HIV and 88.8% (95% CI: 80.3%, 94.5%) among people without HIV. - Authors conclude the regimen’s effectiveness was excellent; adverse events were common but manageable and did not appear to substantially affect treatment success. - Findings were consistent across HIV status, supporting use of the regimen in settings with high HIV prevalence. - Study received ethical approvals from the Lesotho Ministry of Health National Ethics Committee and the Harvard Longwood Campus IRB; participants provided written informed consent. - Funding declared from the National Institutes of Health (R01AI46095).
## Clinical Analysis & Structured Key Points
Nine-month all-oral regimen for MDR/RR-TB in Lesotho: safety and effectiveness by HIV | medRxiv Skip to main content Nine-month all-oral regimen for MDR/RR-TB in Lesotho: safety and effectiveness by HIV Sara M Sauer , Stephane Mpinda , Allison LaHood , Lawrence Oyewusi , Refiloe Maime , Joalane Makaka , Mahooe Thoakana , Daniel Monyaesa , Litsoanelo Musa , Tlotlisang Thai , Letizia Trevisi , Elna Osso , Phate Sebakeng , Meseret Tamirat , Marguerite Curtis , Andrew Lindeborg , Edmund Shen , Michael L Rich , Carole Mitnick , Kwonjune Seung , View ORCID Profile Molly F Franke , Mikanda K Kunda , Llang Maama doi: https://doi.org/10.64898/2026.09.04.26362253 Sara M Sauer 1 Harvard Medical School; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Stephane Mpinda 2 Partners In Health Lesotho; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Allison LaHood 1 Harvard Medical School; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Lawrence Oyewusi 2 Partners In Health Lesotho; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Refiloe Maime 2 Partners In Health Lesotho; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Joalane Makaka 2 Partners In Health Lesotho; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Mahooe Thoakana 2 Partners In Health Lesotho; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Daniel Monyaesa 2 Partners In Health Lesotho; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Litsoanelo Musa 2 Partners In Health Lesotho; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Tlotlisang Thai 2 Partners In Health Lesotho; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Letizia Trevisi 1 Harvard Medical School; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Elna Osso 1 Harvard Medical School; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Phate Sebakeng 2 Partners In Health Lesotho; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Meseret Tamirat 2 Partners In Health Lesotho; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Marguerite Curtis 1 Harvard Medical School; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Andrew Lindeborg 1 Harvard Medical School; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Edmund Shen 1 Harvard Medical School; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Michael L Rich 3 Brigham and Women's Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Carole Mitnick 1 Harvard Medical School; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Kwonjune Seung 3 Brigham and Women's Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Molly F Franke 1 Harvard Medical School; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Molly F Franke For correspondence: molly_franke{at}hms.harvard.edu Mikanda K Kunda 2 Partners In Health Lesotho; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Llang Maama 4 Ministry of Health, Lesotho Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Background: Individuals living with HIV have been under-represented in operational research and trials of all-oral regimens for multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB) treatment. We report outcomes from a prospective observational cohort study of a nine-month regimen comprised of bedaquiline, linezolid, a fluoroquinolone, delamanid, and clofazimine, in Lesotho, a setting with a high prevalence of HIV infection. Methods: We analyzed patients who initiated the regimen between 2020 and 2023. Overall, and by HIV status, we characterized treatment safety by summarizing the frequency and timing of clinically relevant adverse events. We described treatment effectiveness at the end of treatment and sustained treatment success eighteen months after treatment initiation. Results: Two hundred and fifty-five patients who initiated the shortened all-oral regimen were included in the analysis, of whom 161 (63.1%) were living with HIV. Regardless of HIV status, the most frequent clinically relevant adverse event was peripheral neuropathy, followed by myelosuppression. The estimated unadjusted rates of sustained treatment success at 18 months post-treatment initiation were 86.4% (95% confidence interval (CI): 81.4%, 90.5%) overall, 85.0% (95% CI: 78.2%, 90.4%) among patients living with HIV, and 88.8% (95% CI: 80.3%, 94.5%) among people without HIV. Conclusions: The effectiveness of the nine-month all-oral regimen was excellent. Although adverse events were common, they were manageable and did not appear to substantially impact treatment success. Results were similar regardless of HIV status, supporting the use of this regimen in this population. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was approved by the Lesotho Ministry of Health National Ethics Committee and the Harvard Longwood Campus Institutional Review Board. All participants gave written informed consent. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data produced in the present study are available upon reasonable request to the authors Funder Information Declared National Institutes of Health , R01AI46095 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Next Posted September 09, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Nine-month all-oral regimen for MDR/RR-TB in Lesotho: safety and effectiveness by HIV Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Nine-month all-oral regimen for MDR/RR-TB in Lesotho: safety and effectiveness by HIV Sara M Sauer , Stephane Mpinda , Allison LaHood , Lawrence Oyewusi , Refiloe Maime , Joalane Makaka , Mahooe Thoakana , Daniel Monyaesa , Litsoanelo Musa , Tlotlisang Thai , Letizia Trevisi , Elna Osso , Phate Sebakeng , Meseret Tamirat , Marguerite Curtis , Andrew Lindeborg , Edmund Shen , Michael L Rich , Carole Mitnick , Kwonjune Seung , Molly F Franke , Mikanda K Kunda , Llang Maama medRxiv 2026.09.04.26362253; doi: https://doi.org/10.64898/2026.09.04.26362253 Share This Article: Copy Citation Tools Nine-month all-oral regimen for MDR/RR-TB in Lesotho: safety and effectiveness by HIV Sara M Sauer , Stephane Mpinda , Allison LaHood , Lawrence Oyewusi , Refiloe Maime , Joalane Makaka , Mahooe Thoakana , Daniel Monyaesa , Litsoanelo Musa , Tlotlisang Thai , Letizia Trevisi , Elna Osso , Phate Sebakeng , Meseret Tamirat , Marguerite Curtis , Andrew Lindeborg , Edmund Shen , Michael L Rich , Carole Mitnick , Kwonjune Seung , Molly F Franke , Mikanda K Kunda , Llang Maama medRxiv 2026.09.04.26362253; doi: https://doi.org/10.64898/2026.09.04.26362253 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (616) Allergy and Immunology (898) Anesthesia (330) Cardiovascular Medicine (4790) Dentistry and Oral Medicine (477) Dermatology (412) Emergency Medicine (647) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1621) Epidemiology (15894) Forensic Medicine (32) Gastroenterology (1200) Genetic and Genomic Medicine (7020) Geriatric Medicine (730) Health Economics (1063) Health Informatics (5023) Health Policy (1430) Health Systems and Quality Improvement (1752) Hematology (583) HIV/AIDS (1341) Infectious Diseases (except HIV/AIDS) (16271) Intensive Care and Critical Care Medicine (1167) Medical Education (667) Medical Ethics (153) Nephrology (722) Neurology (7238) Nursing (366) Nutrition (1078) Obstetrics and Gynecology (1236) Occupational and Environmental Health (1002) Oncology (3592) Ophthalmology (1046) Orthopedics (396) Otolaryngology (450) Pain Medicine (469) Palliative Medicine (139) Pathology (705) Pediatrics (1791) Pharmacology and Therapeutics (734) Primary Care Research (762) Psychiatry and Clinical Psychology (5864) Public and Global Health (9734) Radiology and Imaging (2405) Rehabilitation Medicine and Physical Therapy (1443) Respiratory Medicine (1246) Rheumatology (638) Sexual and Reproductive Health (769) Sports Medicine (578) Surgery (774) Toxicology (107) Transplantation (304) Urology (289)
## Related Clinical Research

- [Temporal patterns of tuberculosis-associated hyperglycaemia and effects on treatment outcomes in n](https://medichelpline.com/clinical-feed/plos-one-0-temporal-patterns-of-tuberculosis-associated-hyperglycaemia-and-its-effect-on.md)
- [Urine-based Mtb antigen detection for childhood TB using an ultrasensitive ECL immunoassay](https://medichelpline.com/clinical-feed/medrxiv-16-the-accuracy-of-urine-based-mycobacterial-antigens-to-detect-childhood.md)
- [Predictors of Healthcare Costs for Commercially Insured Adults with Tuberculosis in the US (2013–2](https://medichelpline.com/clinical-feed/medrxiv-0-predictors-of-healthcare-costs-among-commercially-insured-persons-with.md)
- [Determinants of Favorable MDR-TB Treatment Outcomes in Zambia, 2018–2022](https://medichelpline.com/clinical-feed/plos-one-16-determinants-of-favorable-treatment-outcomes-in-multidrug-resistant.md)
- [Gut microbiota and tuberculosis: article content not provided—metadata and access details](https://medichelpline.com/clinical-feed/frontiers-in-immunology-14-gut-microbiota-driven-immunomodulation-in-tuberculosis-targeting-dysbiosis-to.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.